VIVX.F Stock Overview
Focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Avivagen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0072 |
| 52 Week Low | US$0.000001 |
| Beta | -13.76 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -96.43% |
| 33 Year Change | -99.96% |
| 5 Year Change | -99.97% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| VIVX.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 4.2% | 2.0% |
| 1Y | -96.4% | 13.7% | 32.4% |
Return vs Industry: VIVX.F underperformed the US Pharmaceuticals industry which returned 13.7% over the past year.
Return vs Market: VIVX.F underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| VIVX.F volatility | |
|---|---|
| VIVX.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VIVX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine VIVX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | G. F. Anthony | www.avivagen.com |
Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand.
Avivagen Inc. Fundamentals Summary
| VIVX.F fundamental statistics | |
|---|---|
| Market cap | US$7.77k |
| Earnings (TTM) | -US$3.30m |
| Revenue (TTM) | US$508.12k |
0.0x
P/S Ratio0.0x
P/E RatioIs VIVX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIVX.F income statement (TTM) | |
|---|---|
| Revenue | CA$715.22k |
| Cost of Revenue | CA$409.83k |
| Gross Profit | CA$305.39k |
| Other Expenses | CA$4.95m |
| Earnings | -CA$4.64m |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.06 |
| Gross Margin | 42.70% |
| Net Profit Margin | -648.74% |
| Debt/Equity Ratio | -78.1% |
How did VIVX.F perform over the long term?
See historical performance and comparison